303 related articles for article (PubMed ID: 24666391)
21. The role of opioid processes in reward and decision-making.
Laurent V; Morse AK; Balleine BW
Br J Pharmacol; 2015 Jan; 172(2):449-59. PubMed ID: 24930675
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.
Simonson B; Morani AS; Ewald AW; Walker L; Kumar N; Simpson D; Miller JH; Prisinzano TE; Kivell BM
Br J Pharmacol; 2015 Jan; 172(2):515-31. PubMed ID: 24641310
[TBL] [Abstract][Full Text] [Related]
23. In vivo neuronal co-expression of mu and delta opioid receptors uncovers new therapeutic perspectives.
Erbs E; Faget L; Veinante P; Kieffer BL; Massotte D
Receptors Clin Investig; 2014 Sep; 1(5):. PubMed ID: 25938125
[TBL] [Abstract][Full Text] [Related]
24. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
[TBL] [Abstract][Full Text] [Related]
25. Change in functional selectivity of morphine with the development of antinociceptive tolerance.
Macey TA; Bobeck EN; Suchland KL; Morgan MM; Ingram SL
Br J Pharmacol; 2015 Jan; 172(2):549-61. PubMed ID: 24666417
[TBL] [Abstract][Full Text] [Related]
26. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
[TBL] [Abstract][Full Text] [Related]
27. Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.
Moreno E; Quiroz C; Rea W; Cai NS; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; Ferré S
J Neurosci; 2017 Feb; 37(5):1176-1186. PubMed ID: 28007761
[TBL] [Abstract][Full Text] [Related]
28. Emerging areas of opioid pharmacology.
Kelly E; Henderson G; Bailey CP
Br J Pharmacol; 2018 Jul; 175(14):2715-2716. PubMed ID: 29939423
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid-opioid interactions during neuropathic pain and analgesia.
Bushlin I; Rozenfeld R; Devi LA
Curr Opin Pharmacol; 2010 Feb; 10(1):80-6. PubMed ID: 19857996
[TBL] [Abstract][Full Text] [Related]
30. Evidence and Function Relevance of Native DOR-MOR Heteromers.
Cahill CM; Ong E
Handb Exp Pharmacol; 2018; 247():115-127. PubMed ID: 29633181
[TBL] [Abstract][Full Text] [Related]
31. κ Opioid receptor ligands regulate angiogenesis in development and in tumours.
Yamamizu K; Hamada Y; Narita M
Br J Pharmacol; 2015 Jan; 172(2):268-76. PubMed ID: 24417697
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.
Maldonado R; Baños JE; Cabañero D
Br J Pharmacol; 2018 Jul; 175(14):2791-2808. PubMed ID: 29124744
[TBL] [Abstract][Full Text] [Related]
33. Allostery at opioid receptors: modulation with small molecule ligands.
Livingston KE; Traynor JR
Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415
[TBL] [Abstract][Full Text] [Related]
34. Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.
Gomes I; Fujita W; Chandrakala MV; Devi LA
Prog Mol Biol Transl Sci; 2013; 117():207-65. PubMed ID: 23663971
[TBL] [Abstract][Full Text] [Related]
35. β-Arrestin-2 knockout prevents development of cellular μ-opioid receptor tolerance but does not affect opioid-withdrawal-related adaptations in single PAG neurons.
Connor M; Bagley EE; Chieng BC; Christie MJ
Br J Pharmacol; 2015 Jan; 172(2):492-500. PubMed ID: 24597632
[TBL] [Abstract][Full Text] [Related]
36. Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function.
Gomes I; Gupta A; Bushlin I; Devi LA
Front Pharmacol; 2014; 5():268. PubMed ID: 25520661
[TBL] [Abstract][Full Text] [Related]
37. Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs.
Lešnik S; Bertalan É; Bren U; Bondar AN
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948150
[TBL] [Abstract][Full Text] [Related]
38. Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.
Kabli N; Martin N; Fan T; Nguyen T; Hasbi A; Balboni G; O'Dowd BF; George SR
Br J Pharmacol; 2010 Nov; 161(5):1122-36. PubMed ID: 20977461
[TBL] [Abstract][Full Text] [Related]
39. Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.
Cai NS; Quiroz C; Bonaventura J; Bonifazi A; Cole TO; Purks J; Billing AS; Massey E; Wagner M; Wish ED; Guitart X; Rea W; Lam S; Moreno E; Casadó-Anguera V; Greenblatt AD; Jacobson AE; Rice KC; Casadó V; Newman AH; Winkelman JW; Michaelides M; Weintraub E; Volkow ND; Belcher AM; Ferré S
J Clin Invest; 2019 Mar; 129(7):2730-2744. PubMed ID: 30913037
[TBL] [Abstract][Full Text] [Related]
40. Opioid receptors: Structural and mechanistic insights into pharmacology and signaling.
Shang Y; Filizola M
Eur J Pharmacol; 2015 Sep; 763(Pt B):206-13. PubMed ID: 25981301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
